These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 27346339)
81. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Elgamal AA; Troychak MJ; Murphy GP Prostate; 1998 Dec; 37(4):261-9. PubMed ID: 9831223 [TBL] [Abstract][Full Text] [Related]
82. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Thrall MM; DeLoia JA; Gallion H; Avril N Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284 [TBL] [Abstract][Full Text] [Related]
83. Utility of Wang Y; Chow DZ; Ebert E; Tajmir S; Scott JA; Palmer EL AJR Am J Roentgenol; 2020 Oct; 215(4):997-1001. PubMed ID: 32569513 [No Abstract] [Full Text] [Related]
84. Whole-body Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514 [TBL] [Abstract][Full Text] [Related]
85. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023 [TBL] [Abstract][Full Text] [Related]
87. [¹¹C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. Giovacchini G; Incerti E; Mapelli P; Kirienko M; Briganti A; Gandaglia G; Montorsi F; Gianolli L; Picchio M Eur J Nucl Med Mol Imaging; 2015 May; 42(6):877-84. PubMed ID: 25697127 [TBL] [Abstract][Full Text] [Related]
88. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT. Rietbergen DD; van der Hiel B; Vogel W; Stokkel MP Nucl Med Commun; 2011 Dec; 32(12):1143-7. PubMed ID: 22045476 [TBL] [Abstract][Full Text] [Related]
89. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Hricak H; Schöder H; Pucar D; Lis E; Eberhardt SC; Onyebuchi CN; Scher HI Semin Oncol; 2003 Oct; 30(5):616-34. PubMed ID: 14571410 [TBL] [Abstract][Full Text] [Related]
90. Detection of a second malignancy in prostate cancer patients by using [(18)F]Choline PET/CT: a case series. Sollini M; Pasqualetti F; Perri M; Coraggio G; Castellucci P; Roncali M; Boni R; Lazzeri E; Galeandro M; Paiar F; Versari A; Erba PA Cancer Imaging; 2016 Aug; 16(1):27. PubMed ID: 27581366 [TBL] [Abstract][Full Text] [Related]
91. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554 [TBL] [Abstract][Full Text] [Related]
92. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187 [TBL] [Abstract][Full Text] [Related]